-
Blood: Immune escape from PD-1 is a defining feature of large B-cell lymphoma rich in T-cells/tissue cells.
Time of Update: 2020-09-23
, the unbiased aggregation of spatially differentiated immune characteristics distinguishes TCRLBCL from the associated B-cell lymphoma subtypes, including classic Hodgkin's lymphoma and DLBCL-NOS.
-
Blood: Characteristics of pDC-AML and potential treatment strategies.
Time of Update: 2020-09-23
runX1 mutation is the most common somogenal cell mutation in pDC-AML, and is more common than AML without pDC amplification and BPDCN.
leukemia mother cells, which are the source of RUNX-mutant AML, can be adjusted for pDC transcription, allowing cells to differentiate and amplification to pDC.
-
NEJM:BIVV001 maintains long-term high levels of VIII factor activity in patients with severe type A haemophilia.
Time of Update: 2020-09-23
the geometric average half-life of BIVV001 is 3 to 4 times that of recombined VIII factors (low dose group: 37.6 vs 9.1 hours, high dose group: 42.5 vs 13.2 hours).
-
Blood: VEGF-C protects the integrity of the micro-environment around bone marrow blood vessels.
Time of Update: 2020-09-22
and chemotherapy can damage the micro-environment of HSC, including its sinus-like blood vessels and vascular cells, leading to a slow recovery of hematosis.
, the study shows that preserving the integrity of the micro-environment around blood vessels through VEGF-C signals may be an effective treatment to enhance hema production regeneration.
-
Blood: Different mutations in GGCX have different effects on the biological function of vitamin K-dependent proteins.
Time of Update: 2020-09-22
results show that GGCX mutations have different effects on the efflurgization of these reported proteins and the efficiency of vitamin K as a cofactor.
-
Lancet: The "dose reduction strategy" of double antiplate plate plate therapy significantly improved the postoperative prognosis of PCI in patients with acute coronary syndrome.
Time of Update: 2020-09-22
the main endpoint of the disease is a year of net adverse clinical events (all due to death, non-fatal myocardial infarction, stent thrombosis, repeated vascular reconstruction, stroke, and level 2 bleeding).
-
Lancet: Liso-cel treatment of recurring/resuscable large B-cell lymphoma is active and safe.
Time of Update: 2020-09-22
patients with relapsed or resuscable large B-cell lymphoma were treated with liso-cel to obtain a higher objective remission rate, and a low rate of cytokine release syndrome and neurological events at level 3.
-
Lancet: Preoperative iron therapy does not improve the need for postoperative blood transfusions in anemia patients.
Time of Update: 2020-09-22
recently examined the effects of preoperative iron therapy on reducing blood transfusion needs and patient prognosis in patients with anemia undergoing selected abdominal surgery.
study concluded that intravenous iron therapy in patients with anemia 10-42 days before selected abdominal surgery could not reduce the need for blood transfusions after surgery.
-
Inventory: A selection of Blod research on August 20, 2020.
Time of Update: 2020-09-22
recently, researchers found that the overexpeaturalization of SNAI1, a key regulatory factor of EMT, is a pathologically related event in human acute myeloid leukemia (AML), which can lead to impaired, self-renewal, and proliferation of immature myelin cell differentiation.
-
Rozanolixizumab Treatment of Primary Immunocompyte plate plate plate reduction: Positive progress has been made in Phase II studies.
Time of Update: 2020-09-22
In this study, clinical improvements in plate plate count (i.e., plate plate count of 50x109/L) and immunoglobulin G (IgG) were observed in the single dose group (15 and 20 mg / kg) and the multi-dose group (5x4, 3x7 and 2x10 mg / kg per week, with a cumulative dose of approximately 20 mg / kg).
-
And Platinum Pharmaceuticals completed the B-plus round of financing of $75 million and C round of financing of $100 million, at the Cell Engager Summit to show its BCMAxCD3 dual specific antibodies.
Time of Update: 2020-09-22
HBM7020 can overcome certain limitations and become a new generation therapy for multiple myeloma, selectively removing BCMA-positive MM cells with less cytokine release.
compared to rival Regeneron's BCMAxCD3 dual-specific antibodies, HBM7020 effectively kills BCMA-positive MM cells and reduces the risk of CRS (cytokine release syndrome).
-
Blood: Lipid metabolic enhancement mediates impaired function of NK cells in lymphoma.
Time of Update: 2020-09-22
found that NK cells underwent extensive transcriptional reprogramming in invasive B-cell lymphoma, accompanied by lipid metabolism enhancement, including elevated expression levels of the transcription regulator PPAR-g.
, this study shows that enhancing lipid metabolism while impairing its function is the functional adaptation of NK cells to fatty acid-rich lymphoma environments.
-
Blood: The effect of Getuzumab ozogamicin treatment on MRD and recurrence risk in patients with NPM1 mutation AML.
Time of Update: 2020-09-22
with MRD-positive patients with GO treatment, the transcription level of NPM1-mut decreased significantly after two courses, and the CIR rate decreased significantly (4 years CIR 29.3% vs 45.7%, P .009).
-
Blood: P53 activation during the occurrence of nuclear glycosome organisms regulates normal red system differentiation.
Time of Update: 2020-09-22
(effects of CX-5461 treatment on the structure of human red blood cell prescellular nuclei) suggests that the time when nuclear glycosome organisms stop and p53 is activated is critical to red line development.
-
Blood: Breaking the MALT1 feedback mechanism may maximize the anti-lymphoma efficacy of MALT1 inhibitors.
Time of Update: 2020-09-22
In these cell line, inhibition of MALT1 promotes an increase in mTORC1 activity and phosphorylation levels in S6K1-T389 and S6-S235/6, which is only partially blocked by PI3Kd inhibition inside and outside the body.
-
Blood: 4 IKAROS embryonic mutations that cause a variety of blood diseases, including malignant tumors.
Time of Update: 2020-09-22
in a recent article in the journal Blood, Germline IKAROS dimerization haploinsufficicity causes hematologic cytopenias and malignancies, the researchers outlined four ICARS embryo hybrid mutations that affected ICAROS's N-end dimpolymer functional domain through a single dose deficiency, from four unrelated families.
-
Blood: Prognosis of bone marrow transplantation between unhyorly umbilical cord blood and HLA hydromethosome.
Time of Update: 2020-09-22
2-year progression survival rate after umbilical cord blood and monolithic combined transplantation was 35% (95% CI 28-42%) and 41% (34-48%, p-0.41), respectively.
, there was no statistical difference between the main endpoints of the two transplant sources and the two-year non-progression survival rates.
-
A selection of Blod research on August 27, 2020.
Time of Update: 2020-09-22
1. Ipale Net corrects glycogen storage IB's neutral granulocyte reduction and its dysfunction https://doi.org/10.1182/blood.2019004465 Neutral granulocyte reduction and neutral granulocyte dysfunction
-
GUT: Xu Zhengping/Sheng Jinghao team found that angiogen can maintain the stability of the intestinal bacteriocytes to prevent the occurrence of enteritis.
Time of Update: 2020-09-22
Recently, Xu Zhengping/Sheng Jinghao Group of Zhejiang University School of Medicine, Liangyu Laboratory (Systems Medicine and Precision Diagnosis and Treatment Zhejiang Laboratory) published a resear
-
The FDA has granted Bcl-2 inhibitor APG-2575 orphan drug eligibility for the treatment of chronic lymphocytic leukemia.
Time of Update: 2020-09-22
Biotech company Aachen Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has awarded the new Bcl-2 inhibitor APG-2575 orphan drug title (ODD) for the treatment of chronic lymphocytic leukemia (CLL).
APG-2575 is a new oral Bcl-2 selective inhibitor developed by Asaan Pharmaceuticals.
